Passing the first hurdle, U.S. Rep. Arrington's multi-cancer early detection screening bill receives full bipartisan support ...
The firm is betting on pairing KTX-1001 with BMS's mezigdomide and Onyx's Pomalyst in a crowded, competitive field.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback